The withdrawal of Philips’ V60 ventilator is creating a large replacement cycle across U.S. hospitals.

For hospitals that have relied on the V60 for years, replacing the device involves much more than purchasing another ventilator. Existing breathing circuits and accessories may no longer be compatible; respiratory therapists may need to learn a new interface; new equipment needs to connect with central monitoring systems; biomedical engineering teams need local service support; and hospitals need to reassess parts availability and supply continuity.

All of these switching costs can quickly add up.

Mindray is positioning its newly launched SV70 Non-Invasive Ventilator around precisely these issues.

The SV70 was officially launched in North America on September 15, 2026. Mindray describes the system as a non-invasive ventilation platform designed to support hospitals transitioning away from the Philips V60.

Replacing a V60 Means Replacing More Than One Machine

The commercial withdrawal of the Philips V60 means hospitals need to determine what parts of their existing respiratory-care workflow will need to change.

For a hospital, the questions include:

• Can existing breathing circuits and accessories still be used?

• Will respiratory therapists need to learn a completely different operating interface?

• Can data from the new ventilator connect with the hospital’s existing central monitoring system?

• Is local biomedical engineering support available?

• How long will parts and accessories remain available?

• How much retraining, IT integration and workflow redesign will be required?

Mindray has designed the SV70 around these transition costs.

From a workflow perspective, the SV70 shares a single-limb circuit architecture with the Philips V60 and is positioned to preserve familiar ventilation settings and workflows. Mindray also states that the SV70 can integrate with its BeneVision N-Series patient monitoring ecosystem.

The system combines non-invasive ventilation with integrated high-flow oxygen therapy, allowing clinicians to switch between NIV and high-flow oxygen therapy without changing devices. It is intended for adult and pediatric patients weighing at least 20 kg.

Mindray’s broader SV-Series portfolio, including the SV900, SV700 and now the SV70, therefore covers invasive ventilation, non-invasive ventilation and high-flow oxygen therapy.

There is one important boundary to note.

Philips’ V60 and V60 Plus have been discontinued, but Philips has stated that service and support will continue through December 2029, subject to parts availability. The FDA’s regulatory treatment of predicate devices also does not mean that a new ventilator is necessarily clinically interchangeable with every V60 use scenario.

From a Single Product to an Acute-Care Platform: Mindray’s 2026 North American Moves

The SV70 is not an isolated product launch.

Mindray has made a series of moves in North America during 2026.

In January, the company expanded its strategic collaboration with a major U.S. healthcare network from hospital operations into ambulatory surgery centers.

On March 18, Mindray launched its SV900 and SV700 ventilators in the U.S., marking its formal entry into the North American ventilator market.

On September 2, Mindray North America completed the expansion of its warehouse in Mahwah, New Jersey. The project added 46,314 square feet, bringing the facility to a total of 80,979 square feet. Mindray said the expansion would centralize logistics operations and improve order fulfillment.

On September 15, the SV70 was officially launched, directly targeting hospitals transitioning from the Philips V60.

Taken together, these steps suggest that Mindray is building more than a single ventilator business in the U.S.

The company is gradually assembling a platform that includes critical-care equipment, patient monitoring, data connectivity, local logistics and service support.

For large hospital systems, the value of such a model lies in standardization.

Hospitals increasingly prefer vendors that can provide not only individual devices but also a unified interface, connected monitoring systems, long-term service support and predictable supply.

Mindray’s financial results also show the growing importance of international markets.

In the first half of 2026, the company reported RMB 9.471 billion in international revenue, up 13.67% year on year, accounting for 53.37% of total revenue. In U.S.-dollar terms, international revenue increased 18.42%.

The North American respiratory-care push therefore fits into a broader shift in the company’s revenue structure toward overseas markets.

Chinese Medtech Going Global: From “Selling Equipment” to “Taking Over Installed Bases”

Chinese medical-device companies expanding overseas often follow a familiar route: launch a new product, identify distributors, obtain regulatory approval, and then compete for hospital purchases.

Mindray’s approach in this case is different.

Rather than entering an empty market, the company is targeting an existing installed base created by a withdrawing incumbent.

This is a classic replacement-market strategy.

When a large incumbent exits, the key opportunity is not simply that “one competitor disappears.” The more important question is whether another supplier can convert the incumbent’s installed base into its own long-term platform customers by lowering the cost of switching.

That requires more than a competitive product price.

Hospitals also need:

• accessory and consumable compatibility

• familiar operating workflows

• lower retraining costs

• connectivity with existing monitoring infrastructure

• local logistics

• long-term parts availability

• reliable service support

Each of these factors can reduce the friction of changing suppliers.

This is different from many earlier globalization efforts by Chinese medtech companies, which often centered on regulatory registration, distributor recruitment and expansion into emerging markets.

Here, the competitive challenge is taking over demand that is already established inside mature hospitals.

The core question is therefore whether Mindray can make the transition from Philips equipment smooth enough for hospitals to accept.

Several Questions Still Need to Be Answered

The replacement opportunity is real, but the competitive window is not unlimited.

Philips has discontinued the V60 and V60 Plus, yet it will continue service and support through the end of 2029 as long as parts remain available. Hospitals can therefore replace their fleets gradually rather than all at once.

Mindray is also not entering an uncontested market.

The U.S. respiratory-care market includes established companies such as Hamilton Medical, Dräger, Nihon Kohden and Getinge, among others.

For large U.S. hospital networks, purchasing decisions often involve GPO contracts, service coverage, cybersecurity review, health IT integration and total cost of ownership.

Mindray therefore still needs to prove whether it can gain entry into major hospital procurement systems and convert individual wins into repeat orders.

Several indicators will be worth watching:

• how quickly SV-Series ventilators gain installations and repeat orders in large U.S. IDNs

• whether SV70 and BeneVision can increase cross-product penetration within the same hospitals

• whether the company’s U.S. respiratory-care revenue becomes a meaningful contributor to international growth

• whether local warehousing, technical support and service capabilities reduce switching friction enough to build long-term customer relationships

For Chinese medical-device companies, Mindray’s current U.S. strategy offers a different globalization case study.

The next stage of international expansion may not always come from entering greenfield markets.

In some cases, the opportunity may come when an established multinational withdraws, leaving behind a large installed base that needs replacement.

The companies best positioned to capture that opportunity will be those that can combine product compatibility, workflow continuity, data connectivity and local service capabilities into a complete replacement solution.

September 18, 2026